A dual-specific macrophage colony-stimulating factor antagonist of c-FMS and α<sub>v</sub>β<sub>3</sub> integrin for osteoporosis therapy

by Yuval Zur, Lior Rosenfeld, Chen Anna Keshelman, Nofar Dalal, Gali Guterman-Ram, Ayelet Orenbuch, Yulia Einav, Noam Levaot, Niv Papo

There is currently a demand for new highly efficient and specific drugs to treat osteoporosis, a chronic bone disease affecting millions of people worldwide. We have developed a combinatorial strategy for engineering bispecific inhibitors that simultaneously target the unique combination of c-FMS and αvβ3 integrin, which act in concert to facilitate bone resorption by osteoclasts. Using functional fluorescence-activated cell sorting (FACS)-based screening assays of random mutagenesis macrophage colony-stimulating factor (M-CSF) libraries against c-FMS and αvβ3 integrin, we engineered dual-specific M-CSF mutants with high affinity to both receptors. These bispecific mutants act as functional antagonists of c-FMS and αvβ3 integrin activation and hence of osteoclast differentiation in vitro and osteoclast activity in vivo. This study thus introduces a versatile platform for the creation of new-generation therapeutics with high efficacy and specificity for osteoporosis and other bone diseases. It also provides new tools for studying molecular mechanisms and the cell signaling pathways that mediate osteoclast differentiation and function.

Source link

Related posts

The Role of Auxin in the Pattern Formation of the Asteraceae Flower Head (Capitulum)


Fight Aging! Newsletter, June 10th 2019


State of (In)flux: Action of a CNGC Ca2+ Channel in Defense against Herbivory


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy